187 related articles for article (PubMed ID: 34535610)
1. LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clindamycin Solution in Hurley I and II Hidradenitis Suppurativa: Results from Period A of RELIEVE, a Multicenter Randomized, Controlled Trial.
Schultheis M; Staubach P; Nikolakis G; Grabbe S; Ruckes C; von Stebut E; Kirschner U; Matusiak Ł; Szepietowski JC
Dermatology; 2022; 238(3):476-486. PubMed ID: 34535610
[TBL] [Abstract][Full Text] [Related]
2. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.
Caposiena Caro RD; Cannizzaro MV; Botti E; Di Raimondo C; Di Matteo E; Gaziano R; Bianchi L
J Am Acad Dermatol; 2019 May; 80(5):1314-1321. PubMed ID: 30502416
[TBL] [Abstract][Full Text] [Related]
3. Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation.
Caposiena Caro RD; Molinelli E; Brisigotti V; Offidani A; Bianchi L
Clin Exp Dermatol; 2021 Jan; 46(1):96-102. PubMed ID: 32683727
[TBL] [Abstract][Full Text] [Related]
4. Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa.
Aarts P; van Huijstee JC; van der Zee HH; van Straalen KR; Prens EP
J Eur Acad Dermatol Venereol; 2024 May; 38(5):904-909. PubMed ID: 38112226
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness and safety of the LAight-therapy in patients with hidradenitis suppurativa.
Strobel A; Schultheis M; Staubach P; Grabbe S; Mann C; Hennig K; Szepietowski JC; Matusiak L; Krajewski P; von Stebut E; Garcovich S; Bayer H; Heise M; Podda M; Kirschner U; Nikolakis G
J Dtsch Dermatol Ges; 2024 May; ():. PubMed ID: 38807028
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of radiofrequency in the treatment of hidradenitis suppurativa; a systematic review.
Nilforoushzadeh MA; Heidari N; Heidari A; Ghane Y; Hosseini S; Lotfi Z; Jaffary F; Nobari MN; Aghamiri ZS; Nobari NN
Lasers Med Sci; 2024 May; 39(1):139. PubMed ID: 38795173
[TBL] [Abstract][Full Text] [Related]
7. Combining Deroofing with LAight
Schultheis M; Scheuern M; Radkov I
Clin Pract; 2021 Jan; 11(1):26-31. PubMed ID: 33506816
[TBL] [Abstract][Full Text] [Related]
8. [Impact of LAight therapy on hidradenitis suppurativa care].
Zimmer S; Basien K; von Stebut E
Hautarzt; 2021 Jul; 72(7):586-594. PubMed ID: 34125251
[TBL] [Abstract][Full Text] [Related]
9. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment.
Rondags A; van Straalen KR; van Hasselt JR; Janse IC; Ardon CB; Vossen ARJV; Prens EP; van der Zee HH; Horváth B
Br J Dermatol; 2019 May; 180(5):1214-1220. PubMed ID: 30512186
[TBL] [Abstract][Full Text] [Related]
10. [Topical and novel device-based therapies for mild hidradenitis suppurativa].
Nikolakis G; von Stebut E
Hautarzt; 2021 Aug; 72(8):676-685. PubMed ID: 34223936
[TBL] [Abstract][Full Text] [Related]
11. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort.
van Straalen KR; Tzellos T; Alavi A; Benhadou F; Cuenca-Barrales C; Daxhelet M; Daoud M; Efthymiou O; Giamarellos-Bourboulis EJ; Guillem P; Gulliver W; Jemec GBE; Katoulis A; Koenig A; Lazaridou E; Lowes MA; Marzano AV; Matusiak L; Molina-Leyva A; Moltrasio C; Pinter A; Potenza C; Prens EP; Romaní J; Saunte DM; Sayed C; Skroza N; Stergianou D; Szepietowski JC; Trigoni A; Vilarrasa E; Kyrgidis A; Zouboulis CC; van der Zee HH
Dermatology; 2023; 239(3):362-367. PubMed ID: 36630943
[TBL] [Abstract][Full Text] [Related]
12. Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa.
Rosi E; Pescitelli L; Ricceri F; Di Cesare A; Novelli A; Pimpinelli N; Prignano F
Dermatol Ther; 2019 Mar; 32(2):e12792. PubMed ID: 30515931
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized controlled trial assessing the efficacy of adjunctive hyperbaric oxygen therapy in the treatment of hidradenitis suppurativa.
Yildiz H; Senol L; Ercan E; Bilgili ME; Karabudak Abuaf O
Int J Dermatol; 2016 Feb; 55(2):232-7. PubMed ID: 26267600
[TBL] [Abstract][Full Text] [Related]
14. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study.
van Straalen KR; Tzellos T; Guillem P; Benhadou F; Cuenca-Barrales C; Daxhelet M; Daoud M; Efthymiou O; Giamarellos-Bourboulis EJ; Jemec GBE; Katoulis AC; Koenig A; Lazaridou E; Marzano AV; Matusiak Ł; Molina-Leyva A; Moltrasio C; Pinter A; Potenza C; Romaní J; Saunte DM; Skroza N; Stergianou D; Szepietowski J; Trigoni A; Vilarrasa E; van der Zee HH
J Am Acad Dermatol; 2021 Aug; 85(2):369-378. PubMed ID: 33484766
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a combined pharmacological and surgical approach in patients affected by hidradenitis suppurativa: data from a retrospective real-world clinical study.
Malvaso D; Chiricozzi A; Fossati B; Antonelli F; Peris K
Ital J Dermatol Venerol; 2024 Apr; 159(2):190-195. PubMed ID: 38650499
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T
Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295
[TBL] [Abstract][Full Text] [Related]
19. Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system.
Scheinfeld N
Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617596
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of medical and surgical treatments for hidradenitis suppurativa using real-life data from the Scandinavian registry (HISREG).
Grimstad Ø; Tzellos T; Dufour DN; Bremnes Ø; Skoie IM; Snekvik I; Jarnaess E; Kyrgidis A; Ingvarsson G
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1164-1171. PubMed ID: 30451320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
